���疫调节机制与信号 — 2026 Update

By Editorial Desk · published 2026-04-12 · last reviewed 2026-05-31 · Wiki

A practical reference on thymosin alpha-1: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

This page was last updated on 2026-05-31 and is reviewed periodically as new material appears.

免疫调节机制与信号

胸腺素α1对免疫系统的影响涉及多种细胞类型。研究表明，它可促进未成熟T细胞向成熟T细胞分化，并增强T细胞对抗原刺激的增殖反应。树突状细胞在Tα1存在下表达更高水平的共刺激分子，从而更有效地呈递抗原。此外，自然杀伤细胞的活性也观察到上升。这些效应并非直接杀伤病原体，而是调节宿主免疫应答的强度与方向。

在信号层面，Tα1可能通过Toll样受体等模式识别受体发挥作用。部分实验显示，它能激活髓样分化因子88依赖的通路，进而促进核因子κB进入细胞核。这导致白细胞介素2、干扰素γ和白细胞介素12等细胞因子的转录增加。这些细胞因子偏向辅助性T细胞1型应答，有助于细胞免疫。然而，具体受体和结合位点尚未完全确定，不同实验模型的结果存在差异。

临床研究将Tα1用于慢性病毒感染、肿瘤辅助治疗和疫苗佐剂等场景。部分试验报告了免疫学指标改善，但临床终点获益在不同研究中并不一致。系统综述指出，研究间在人群、剂量和联合方案上差异较大，难以汇总结论。因此，Tα1的确切临床地位仍属开放问题，需要更多高质量随机对照试验来澄清。其机制研究也需从体外实验向体内模型推进。

Molecular Identity Of Thymosin Alpha-1

Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.

Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.

Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.

Thymosin-alpha-1 at a glance

Analytical Methods and Storage Stability

The lyophilized peptide is generally stable for extended periods when kept cold and dry. Once dissolved, aqueous solutions are less stable; hydrolysis, oxidation, and aggregation can degrade the material. Storage at -20 °C or lower slows these processes. Repeated freeze-thaw cycles are best avoided because they can promote aggregation. The exact shelf life depends on formulation, pH, and concentration, so stability studies are typically performed for each specific product.

Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.

Related pages on this site

• Efficient collection
• Seasonal archive
• Practical dataset
• Connected comparison
• Portable overview
• Focused analysis
• Sustainable analysis
• Modular briefing

Molecular Background and Immune Action

Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.

Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.

Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.

Further detail

=== Complications === Complications may include urinary retention, recurring urinary tract infections and incontinence. The anterior vaginal wall may protrude though the vaginal introitus (opening). This can interfere with sexual activity. Recurrent urinary tract infections are common for those who have urinary retention. In addition, though cystocele can be treated, some treatments may not alleviate troubling symptoms, and further treatment may need to be performed. Cystoceles may affect the quality of life; women who have cystoceles tend to avoid leaving their homes and avoid social situations. The resulting incontinence puts women at risk of being placed in a nursing home or long-term care facility.

Notwithstanding, nutrition labels on Australian food products typically recommend the average daily energy intake of 8,800 kJ (2,100 kcal). The minimum food energy intake is also higher in cold environments. Increased mental activity has been linked with moderately increased brain energy consumption.

== Ideology == SPUSA argues that socialism can only come through social revolution. SPUSA tendencies include both democratic socialism, for a gradual transformation of society, and revolutionary socialism, for a rapid transformation following a slow "socialist transformation from below" through radically democratic "people's organizations". SPUSA describes socialism as a radically democratic system which "places people's lives under their own control—a classless, feminist, socialist society free of racism, sexism, homophobia or transphobia," and in which "the people own and control the means of production and distribution through democratically controlled public agencies, cooperatives, or other collective groups"; "full employment is realized for everyone who wants to work"; "workers have the right to form unions freely, and to strike and engage in other forms of job actions"; and "production of society is used for the benefit of all humanity, not for the private profit of a few." Socialist Party candidates support expanding social spending and social ownership of capital. In 2009, Greg Pason's proposals included socializing the United States health care system, a steeply graduated income tax, universal rent control and the elimination of all educational debts and tuition fees. In 1997, Pason called auto insurance "a regressive tax against working people". Moore was also vocal of his support for socialized medicine. Moore supported economic democracy through social ownership and workers' control of reigning industrial and financial institutions.

Sources: en.wikipedia.org

Background from the literature

Nobody's done that before." In February 2012, the Smithsonian National Museum of American History announced that Ayyadurai had donated "a trove of documents and code" related to EMAIL. Initially, the museum—inaccurately—cited the program as one of the first to include the now common "subject and body fields, inboxes, outboxes, cc, bcc, attachments, and others. He based these elements directly off of the interoffice mail memos the doctors had been using for years, in hopes of convincing people to actually use the newfangled technology." Ayyadurai's claims drew editorial clarifications and corrections, as well as criticism from industry observers. In a followup to its acquisition announcement, the Smithsonian stated that it was not claiming that Ayyadurai had invented email, but rather that the materials were historically notable for other reasons related to trends in computer education and the role of computers in medicine. The Smithsonian statement distinguished Ayyadurai's achievement by noting that historians in the field, "have largely focused on the use of large networked computers, especially those linked to the ARPANET in the early 1970s". The statement observed that Ayyadurai's approach instead "focused on communications between linked computer terminals in an ordinary office situation".

E-liquids were purchased from retailers and via online for a 2013 study. The Royal College of General Practitioners stated in 2016 that "To date 42 chemicals have been detected in ENDS aerosol – though with the ENDS market being unregulated there is significant variation between devices and brands." E-liquid nicotine concentrations vary. The amount of nicotine stated on the labels of e-liquids can be very different from analyzed samples. Some e-liquids sold as nicotine-free contained nicotine, and some of them were at substantial levels. The analyzed liquids nicotine levels were between 14.8 and 87.2 mg/mL and the actual amount varied from the stated amount by as much as 50%. Possibly, 60–70% of the nicotine is vaporized. E-cigarettes without nicotine is also available. Via nicotine-containing e-cigarettes, nicotine is absorbed through the upper and lower respiratory tract. A greater amount of nicotine is possibly absorbed through oral mucosa and upper airways. The composition of the e-liquid may affect nicotine delivery. E-liquid containing glycerin and propylene glycol delivers nicotine more efficiently than a glycerin-based liquid with the same amount of nicotine. It is believed that propylene glycol vaporizes quicker than glycerin, which subsequently transports a higher amount of nicotine to the user. Vaping appears to give less nicotine per puff than cigarette smoking.

=== Differential diagnoses === The muscle weakness that worsens with activity (abnormal muscle fatigue) in myasthenia gravis is a symptom shared by other neuromuscular diseases. Most of the metabolic myopathies, such as McArdle disease (GSD-V), have abnormal muscle fatigue rather than fixed muscle weakness. Also, like myasthenia gravis, exercise intolerance in McArdle disease improves with regular physical activity (performed safely using activity adaptations such as getting into second wind, the "30 for 80 rule," and "six second rule"). A small minority of people with McArdle disease also have the comorbidity of ptosis (drooping upper eyelid). Late-onset GSD-II (Pompe disease) and GSD-XV also have muscle weakness or fatigue with comorbidities of ptosis and ophthalmoplegia; as do many of the mitochondrial myopathies. Other diseases that involve abnormal muscle fatigue (which may be described as exercise-induced muscle weakness, reversible muscle weakness, or muscle weakness that improves with rest) include: endocrine myopathies (such as Hoffman syndrome), Tubular aggregate myopathy (TAM), ischemia (such as intermittent claudication, popliteal artery entrapment syndrome, and chronic venous insufficiency), and poor diet or malabsorption diseases that lead to vitamin D deficiency (osteomalic myopathy). Although limb-girdle muscular dystrophies (LGMDs) involve fixed muscle weakness, LGMDR8 also involves muscle fatigue; as do some limb-girdle muscular dystrophy-dystroglycanopathies such as MDDGC3 (a.k.a. LGMDR15 and LGMD2O).

In the West, the decision was made through the 1957 Treaty of Rome to launch the first European Economic Community. It shared the Assembly and Court with the Coal and Steel Community, but set up parallel bodies for the Council and Commission. Based on the Spaak Report of 1956, it sought to break down all barriers to trade in a common market for goods, services, labour and capital, and prevent distortion of competition and regulate areas of common interest like agriculture, energy and transport. A separate treaty was signed for a European Atomic Energy Community to manage nuclear production. In 1961 the United Kingdom, Denmark, Ireland and Norway applied for membership only to be vetoed in 1963 by France's Charles de Gaulle. Spain also applied and was rejected as it was still led by the Franco dictatorship. The same year, the Court of Justice proclaimed that the Community constituted a "new legal order of international law". The Merger Treaty finally placed the ECSC and Euratom within the EEC. Shortly after, de Gaulle boycotted the commission, which he believed was pressing supranationalism too far. The Luxembourg compromise in 1966 agreed that France (or other countries) could veto issues of "very important national interest", particularly relating to the Common Agricultural Policy, instead of making decisions by "qualified majority". But after the May 1968 events in France and de Gaulle's resignation, the way was free for the United Kingdom, Ireland, and Denmark to join in 1973.

Sources: en.wikipedia.org

Frequently asked questions